Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors

Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Hambach, Julia, Mann, Anna Marei, Bannas, Peter, Koch-Nolte, Friedrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668101/
https://www.ncbi.nlm.nih.gov/pubmed/36405759
http://dx.doi.org/10.3389/fimmu.2022.1005800
_version_ 1784831840809385984
author Hambach, Julia
Mann, Anna Marei
Bannas, Peter
Koch-Nolte, Friedrich
author_facet Hambach, Julia
Mann, Anna Marei
Bannas, Peter
Koch-Nolte, Friedrich
author_sort Hambach, Julia
collection PubMed
description Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.
format Online
Article
Text
id pubmed-9668101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96681012022-11-17 Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors Hambach, Julia Mann, Anna Marei Bannas, Peter Koch-Nolte, Friedrich Front Immunol Immunology Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma. Frontiers Media S.A. 2022-11-02 /pmc/articles/PMC9668101/ /pubmed/36405759 http://dx.doi.org/10.3389/fimmu.2022.1005800 Text en Copyright © 2022 Hambach, Mann, Bannas and Koch-Nolte https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Hambach, Julia
Mann, Anna Marei
Bannas, Peter
Koch-Nolte, Friedrich
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title_full Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title_fullStr Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title_full_unstemmed Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title_short Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
title_sort targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying aav vectors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668101/
https://www.ncbi.nlm.nih.gov/pubmed/36405759
http://dx.doi.org/10.3389/fimmu.2022.1005800
work_keys_str_mv AT hambachjulia targetingmultiplemyelomawithnanobodybasedheavychainantibodiesbispecifickillercellengagerschimericantigenreceptorsandnanobodydisplayingaavvectors
AT mannannamarei targetingmultiplemyelomawithnanobodybasedheavychainantibodiesbispecifickillercellengagerschimericantigenreceptorsandnanobodydisplayingaavvectors
AT bannaspeter targetingmultiplemyelomawithnanobodybasedheavychainantibodiesbispecifickillercellengagerschimericantigenreceptorsandnanobodydisplayingaavvectors
AT kochnoltefriedrich targetingmultiplemyelomawithnanobodybasedheavychainantibodiesbispecifickillercellengagerschimericantigenreceptorsandnanobodydisplayingaavvectors

Ejemplares similares